MedPath

信达生物制药（苏州）有限公司

Ownership
-
Established
2011-08-24
Employees
-
Market Cap
-
Website
https://www.innoventbio.com

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

6

NMPA:6

Drug Approvals

Teprotumumab N01 Injection

Product Name
信必敏
Approval Number
国药准字S20250013
Approval Date
Mar 11, 2025
NMPA

Tafolecimab Injection

Product Name
信必乐
Approval Number
国药准字S20230043
Approval Date
Nov 10, 2023
NMPA

Sintilimab Injection

Product Name
达伯舒
Approval Number
国药准字S20180016
Approval Date
Jul 13, 2023
NMPA

Bevacizumab Injection

Product Name
达攸同
Approval Number
国药准字S20200013
Approval Date
May 6, 2023
NMPA

Rituximab Injection

Product Name
达伯华
Approval Number
国药准字S20200022
Approval Date
Sep 30, 2020
NMPA

Adalimumab Injection

Product Name
苏立信
Approval Number
国药准字S20200020
Approval Date
Sep 2, 2020
NMPA

Clinical Trials

No trials found

News

No news found
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy